Featured Research

from universities, journals, and other organizations

Rapidly Rising PSA Before Treatment Is Key Indicator Of Cancer Spread

Date:
November 9, 2006
Source:
Fox Chase Cancer Center
Summary:
Results of a new Fox Chase Cancer Center study show that men with a rapidly rising PSA level before treatment have a high probability of metastatic disease and should receive hormone therapy in addition to radiation.

Results of a new Fox Chase Cancer Center study show that men with a rapidly rising PSA level before treatment have a high probability of metastatic disease and should receive hormone therapy in addition to radiation. The findings were presented today at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Philadelphia.

The rate of a rise in PSA level, known as PSA velocity (PSAV), can be used to determine when prostate cancer spread may have already occurred, even in men with clinically localized disease. PSA, or prostate specific antigen, is measured by a blood test and used to determine if prostate cancer is present.

"We've known that men with a rapidly rising PSA are at greater risk of prostate cancer-related death and this study suggests that undetected distant metastasis present prior to radiation therapy may be the cause," explained Mark K. Buyyounouski, M.D., M.S., an attending physician in the radiation oncology department at Fox Chase and lead author of the study. The study looked at data collected between 1989 and 1999 for 671 men with clinically localized prostate cancer who received 3-D conformal radiation therapy.

Buyyounouski and others demonstrated that when the PSAV was greater than 2 ng/ml per year, the PSA was likely to continue rising at the same rate despite radiation therapy to the prostate. What's more, this group of men was found to have a greater likelihood of distant spread of prostate cancer and a greater risk of dying of the disease. This relationship was not seen for men with a slower PSAV of less than 2 ng/ml.

"This study suggests that an initially high PSAV often represents previously undetected metastatic disease exists at the time of diagnosis," said Buyyounouski. "This disease has the opportunity to progress if radiation therapy to the prostate and surrounding tissue is the only treatment," said Buyyounouski. "Therefore, it is recommended that the PSAV be used in addition to other high risk factors to determine if androgen deprivation therapy should be part of the treatment."

Androgen deprivation therapy, or hormone therapy, has been shown to improve survival when used in conjunction with radiation therapy for men at high risk of undetected spread of prostate cancer.

Buyyounouski concluded that requiring a PSAV of less than 2 ng/ml will be important for selecting patients who are most likely to benefit from radiation therapy alone. This has important implications for studies designed to compare various radiation regimens such as hypofractionation.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Rapidly Rising PSA Before Treatment Is Key Indicator Of Cancer Spread." ScienceDaily. ScienceDaily, 9 November 2006. <www.sciencedaily.com/releases/2006/11/061108154857.htm>.
Fox Chase Cancer Center. (2006, November 9). Rapidly Rising PSA Before Treatment Is Key Indicator Of Cancer Spread. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2006/11/061108154857.htm
Fox Chase Cancer Center. "Rapidly Rising PSA Before Treatment Is Key Indicator Of Cancer Spread." ScienceDaily. www.sciencedaily.com/releases/2006/11/061108154857.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins